Cohance

23 July 2026

To
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Scrip Code: 543064

To
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Symbol: COHANCE

Dear Sir/Madam,

Subject: **Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Regulation 10(c) of Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021**

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**SEBI Listing Regulations**") and Regulation 10(c) of the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 (the "**SEBI SBEB Regulations**"), we hereby inform that the Nomination and Remuneration Committee at its meeting held today, i.e. on 23 July 2026 has approved the following:

(a) taking on record of the in-principle approvals issued by BSE Limited and National Stock Exchange of India Limited for the Cohance Lifesciences Limited – Employee Stock Option Plan, 2026 (the "**ESOP 2026**"), vide their letters dated 21 July 2026;

(b) grant of up to 1,97,48,317 stock options to the eligible employees of the Company under the ESOP 2026;

(c) grant of 1,74,843 stock options to the eligible employees of the Company under the Suven Pharmaceuticals Limited – Employee Stock Option Plan – 2023 (the "**ESOP 2023**");

(d) allotment of 30,190 equity shares of the Company of face value of INR 1 each fully paid-up to the options grantees who have exercised the options vested to them under the ESOP 2023; and

(e) with respect to the disclosure made to the stock exchange on 13 March 2026, with respect to grant of 1,98,711 stock options under the ESOP 2023, cancellation of 1,87,703 grants out of such grants. Such cancelled stock options would be available for grant under the ESOP 2023, in accordance with its terms.

The details required to be disclosed under the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 on the above grants are annexed herewith as **Annexure 1** and the details required to be disclosed under the Regulation 10(c) read with Part E of Schedule I of the SEBI SBEB Regulations are annexed herewith as **Annexure 2**.

Kindly take the above on record.

Thanking you.

Yours faithfully,
For **Cohance Lifesciences Limited**
(formerly, Suven Pharmaceuticals Limited)

SISIRA KUMAR MISHRA

Digitally signed by SISIRA KUMAR MISHRA
Date: 2026.07.23 21:17:54 +05'30'

Sisir K. Mishra
Company Secretary & Compliance Officer

Encl: as above

Annexure 1

Details under the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

A. Details of grant of employee stock options under the ESOP 2026.

No	Particulars	Remarks
1	Brief details of Options granted	Up to 1,97,48,317 employee stock options ("**Options**"), which may be offered and granted in one or more tranches, each convertible into one equity share of the Company of face value of INR 1/-
2	Whether the scheme is in terms of SEBI (SBEB) Regulations, 2021 (if applicable)	Yes
3	Total number of shares covered by these options	1,97,48,317
4	Pricing formula	The exercise price per option shall be decided by the board or nomination and remuneration committee and set out in the letter of grant. Provided that in any circumstances, the exercise price shall: (a) not be less than INR 325 (Rupees Three Hundred and Twenty Five only) for any grant that is made within 6 (six) months of the date of receipt of in-principle approval from the stock exchange following the approval of the ESOP 2026 by the shareholders of the Company, provided however that the grant to existing employees of the Company as on the effective date of the ESOP 2026 shall be made within 10 (ten) working days of the date of receipt of in-principle approval from the stock exchanges following the approval of the shareholders, at the exercise price of INR 325 (Rupees Three Hundred and Twenty Five only); or (b) in the case of any grant made after 6 (six) months of the date of receipt of in-principle approval from the stock exchanges following the approval of the shareholders, or any grant to existing employees made after 10 (ten) working days of receipt of in-principle approval from the stock exchanges as set out above, the exercise price shall not be at more than a 20% (twenty percent) discount to the average market price of the shares of the Company over a 21 (twenty-one) trading days' period preceding one trading day prior to the grant date.

5	Options vested	Options granted shall vest not earlier than minimum period of 1 (one) year and not later than maximum period of 8 (eight) years from the date of grant, subject to conditions as set out in the grant letter as issued to respective employees. The Nomination and Remuneration Committee may at its discretion, subject to applicable laws, change the vesting schedule provided that such change is not detrimental in the interest of the employees.
6	Time within which option may be exercised	The exercise period shall be up to 3 years from the date of vesting of options.
7	Options exercised	Not applicable
8	Money realized by exercise of options	Not applicable
9	The total number of shares arising as a result of exercise of option	Not applicable
10	Options lapsed	Not applicable
11	Variation of terms of options	Not applicable
12	Brief details of significant terms	The ESOP 2026 was approved by way of postal ballot by the Company on 13 June 2026. The notice of postal ballot containing the significant terms of ESOP 2026 may be accessed at: https://www.cohance.com/wp-content/uploads/2026/05/Notice-of-Postal-Ballot_May-2026.pdf
13	Subsequent changes or cancellation or exercise of such options	Not applicable
14	Diluted earnings per share pursuant to issue of equity shares on exercise of options	Not applicable

B. Details of grant of employee stock options under the ESOP 2023.

No	Particulars	Remarks
1	Brief details of Options granted	Up to 1,74,843 employee stock options ("**Options**"), which may be offered and granted in one or more tranches, each convertible into one equity share of the Company of face value of INR 1/-
2	Whether the scheme is in terms of SEBI (SBEB) Regulations, 2021 (if applicable)	Yes
3	Total number of shares covered by these options	The Options, upon exercise, shall result in allotment of 1,74,843 shares.
4	Pricing formula	All Options were granted at the exercise price of INR 495.
5	Options vested	Options granted shall vest not earlier than minimum period of 1 (one) year and not later than maximum period of 10 (ten) years from the date of grant, subject to conditions as set out in the grant letter as issued to respective employees. The Nomination and Remuneration Committee may at its discretion, subject to applicable laws, change the vesting schedule provided that such change is not detrimental in the interest of the employees.
6	Time within which option may be exercised	The exercise period shall be up to 3 years from the date of vesting of options.
7	Options exercised	Not applicable
8	Money realized by exercise of options	Not applicable
9	The total number of shares arising as a result of exercise of option	Not applicable
10	Options lapsed	Not applicable
11	Variation of terms of options	Not applicable
12	Brief details of significant terms	Significant terms of the Options have been given in the ESOP 2023, which can be accessed on the website of the Company.
13	Subsequent changes or cancellation or exercise of such options	The Nomination and Remuneration Committee, at its meeting held today, also approved the cancellation of up to 17,90,532 employee stock options under ESOP 2023 pursuant to voluntary surrender by the respective employees; and cancellation of the grant of 1,87,703 stock options previously granted by the Nomination and Remuneration Committee on 13 March 2026.
14	Diluted earnings per share pursuant to issue of equity shares on exercise of options	Not applicable

Annexure 2

Details under the Regulation 10(c) read with Part E of Schedule I of the SEBI SBEB Regulations

No	Particulars	Remarks
1	Company name and address of Registered Office	**Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited)** 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai, Maharashtra, 400093
2	Name of the recognised Stock Exchanges on which the company's shares are listed	BSE Limited (BSE) and National Stock Exchange of India Limited (NSE)
3	Filing date of the statement referred in regulation 10(b) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 with the recognized Stock Exchange	NSE: 19 February 2024 BSE: 19 February 2024
4	Filing Number, if any	NSE: Application No. 40156 BSE: Application No. 195357
5	Title of the Scheme pursuant to which shares are issued, if any	Suven Pharmaceuticals Limited – Employee Stock Option Plan, 2023
6	Kind of security to be listed	Equity shares
7	Par value of the shares	INR 1 per equity share
8	Date of issue of shares /Allotment date	23 July 2026
9	Number of shares issued and allotted	30,190
10	Share Certificate No., if applicable	N.A.

11	Distinctive number of the share, if applicable :	382567141 to 382597330
12	ISIN Number of the shares if issued in Demat	INE03QK01018
13	Exercise price per share	INR 268.18 (As per the ESOP 2023 read with the Scheme of Amalgamation between erstwhile Cohance Lifesciences Limited as the transferor company and the Company as the transferee company, approved by the Hon'ble National Company Law Tribunal vide order dated March 27, 2025).
14	Premium per share	INR 267.18
15	Total issued shares after this issue	38,25,97,330
16	Total issued share capital after this issue	INR 38,25,97,330
17	Details of any lock-in on the shares	N.A.
18	Date of expiry of lock-in	N.A.
19	Whether shares are identical in all respects to existing shares? If not, when will they become identical?	Yes. The above shares rank pari passu and are identical in all respects to the existing equity shares of the Company.
20	Details of listing fees, if payable	N.A.